Abstract 2788
Background
Deep learning (DL) is one of the best approaches to predict nonlinear behaviors from high dimensional data. Nevertheless predicting the outcome of patients affected by cancers from transcriptomic data has shown limited performance, even with DL (C-index usually <0.65). Transfer learning is a DL two-step method where a model is pre-trained for a basic task on large amount of data, and then fine-tuned on the aimed task. We hypothesized that using TL with RNAseq may improve the performances of cancer patients’ outcome estimation.
Methods
The model was a Multi-Mayer Perceptron (MLP) with 22913 inputs corresponding to genes bulk tumor whole genome RNAseq expression analysis. An important restriction was applied to the number of units at second layer (N = 100), with further linear decrease across subsequent layers. Architecture of the model (number of layers, skip connections), L1 normalization value and learning rate were optimized by grid search on 30 parallel models. Training was performed using Keras package in R. Data were split into 70% training, 15% cross validation, 15% validation for each step, without contamination between the 2 transfer learning steps. The pre-training step consisted in predicting the organs of sample origin using 17.487 public RNAseq data of normal & cancer tissues (GTEX from gtexportal.org & TCGA from cBioportal.org). Fine-tuning on patients survival used 6401 training tumors. The model’s performance on survival prediction was evaluated by C-index and the area under the survival receiver-operating characteristic curve (AUROC).
Results
The pre-training using GTEx and TCGA reached very high performance with validation accuracy of 0.96 to predict organ of origins for the best model (all models had validation accuracy > 0.9). Fine-tuning on survival, the prognostic performance of the best model on the validation cohort was C-index=0.74 and AUROC= 0.81 (80% of models had a C-index > 0.6). The best model had 8 hidden layers and a small penalization value.
Conclusions
Thanks to this original transfer learning method, we achieved a high performance to estimate cancer patients’ prognostic from whole genome expression, a classically challenging task. Learning on public databases is a valuable method of DL for personalized cancer care.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Angevin: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: BeiGene; Advisory / Consultancy: BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: DebioPharma; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Janssen; Advisory / Consultancy: Lilly; Advisory / Consultancy: MedImmune; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Orion. A. Hollebecque: Advisory / Consultancy: Amgen; Advisory / Consultancy: Spectrum Pharmaceuticals; Advisory / Consultancy: Lilly; Advisory / Consultancy: Debiopharm; Travel / Accommodation / Expenses: Servier; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Lilly; Travel / Accommodation / Expenses: Incyte; Travel / Accommodation / Expenses: Debiopharm. E. Deutsch: Advisory / Consultancy: Boehringer; Advisory / Consultancy: Medimune; Advisory / Consultancy: Amgen; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): biotrachea; Research grant / Funding (institution): BristolMyersSquidd; Research grant / Funding (self): Clevelex; Research grant / Funding (self): EDF; Research grant / Funding (self): Lilly; Research grant / Funding (self): GlaxoSmisthKline; Research grant / Funding (self): Merk; Research grant / Funding (self): Nanobiotix; Research grant / Funding (self): Oseo; Research grant / Funding (self): Ray Search Laboratory; Research grant / Funding (self): Roche; Research grant / Funding (self): Ipsen; Research grant / Funding (self): Servier; Research grant / Funding (self): Takeda. C. Massard: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: BeiGene; Advisory / Consultancy: BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: DebioPharma; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Janssen; Advisory / Consultancy: Lilly; Advisory / Consultancy: MedImmune; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Orion. L. Verlingue: Research grant / Funding (self): Bristol-Myers Squibb; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Adaptherapy. All other authors have declared no conflicts of interest.
Resources from the same session
3842 - Effect of docetaxel-resistance on the reactivity of prostate cancer cells to metformin
Presenter: Jessica Catapano
Session: Poster Display session 3
Resources:
Abstract
5198 - Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response
Presenter: Natalia Jimenez
Session: Poster Display session 3
Resources:
Abstract
2981 - Effect of Selumetinib plus AZD8186 treatment on Cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines
Presenter: Vicenc Ruiz de Porras
Session: Poster Display session 3
Resources:
Abstract
2779 - Anti-tumor activity of cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, in pancreatic ductal adenocarcinoma cells
Presenter: Majid Momeny
Session: Poster Display session 3
Resources:
Abstract
1782 - The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy
Presenter: Han-chung Wu
Session: Poster Display session 3
Resources:
Abstract
1322 - Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients
Presenter: Jens Hahne
Session: Poster Display session 3
Resources:
Abstract
1579 - Serum exosomal microRNA-199b-5p as a novel circulating biomarker to predict response of preoperative chemoradiotherapy for locally advanced rectal cancer
Presenter: Dong Won Baek
Session: Poster Display session 3
Resources:
Abstract
1761 - Live biobank of patient-derived organoids from Thai colorectal cancer patients enables clinical outcome prediction
Presenter: Pariyada Tanjak
Session: Poster Display session 3
Resources:
Abstract
3542 - The biological implications of PDCD6 dysregulation in colorectal cancer
Presenter: Romina Briffa
Session: Poster Display session 3
Resources:
Abstract
4634 - Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas.
Presenter: Mohamed Salem
Session: Poster Display session 3
Resources:
Abstract